Core Insights - The launch of Manlejing® Melatonin Granules, the first drug introduced by Dain Pharmaceutical for improving sleep difficulties in children aged 6-15 with neurodevelopmental disorders, marks a significant milestone in addressing a long-standing clinical gap in China [1][4] - The collaboration between Alibaba Health and Dain Pharmaceutical aims to leverage digital services to meet the unmet health needs of families with children requiring special health care [1][8] Group 1: Product Launch and Collaboration - Manlejing® Melatonin Granules are now available on Alibaba Health, allowing users to purchase the product after prescription verification by professional pharmacists [1] - This product is the first key outcome of a three-year strategic partnership between Alibaba Health and Dain Pharmaceutical, focusing on product innovation [1][8] Group 2: Clinical Significance - Approximately 50% of children with neurodevelopmental disorders in China experience sleep issues, significantly impacting their growth, behavior, and learning abilities [4] - Prior to this launch, there were no approved medications for treating insomnia in children, leaving a critical gap in clinical treatment options [4] Group 3: Product Features and Benefits - Manlejing® Melatonin Granules are the only pediatric-grade melatonin in China, produced under strict GMP standards to ensure quality and consistency [4][5] - Clinical studies indicate that the product can significantly reduce sleep latency within two weeks and improve daytime behavior in children with neurodevelopmental disorders [5] Group 4: Strategic Positioning - Dain Pharmaceutical chose Alibaba Health as a partner due to its ability to connect with a large user base and provide professional pharmaceutical services, ensuring safe medication practices [8] - The platform's authority in content can help parents develop a scientific understanding of sleep issues in children with neurodevelopmental disorders [8] Group 5: Future Product Developments - Dain Pharmaceutical is also set to launch Yikexin® Bovine Colostrum Powder on Alibaba Health, which is a health food certified by the national "blue hat" and focuses on immune regulation [9] - This product contains 17 grams of immunoglobulin (IgG) per 100 grams, providing quantifiable support for immune health [9]

Core Insights - Dain Pharmaceutical has launched the melatonin granules, Manlejing®, for the treatment of sleep disorders in children with neurodevelopmental disorders, marking it as the only approved melatonin medication in China for this purpose [1][2] - The introduction of Manlejing® addresses a significant health challenge, as nearly half of children with conditions like autism spectrum disorder and attention deficit hyperactivity disorder experience sleep issues that affect their overall development [1] Group 1 - Manlejing® is designed in a granule form with a sweet taste, making it easier for children to consume [1] - Clinical studies indicate that after two weeks of using Manlejing®, children's sleep onset latency is reduced by over 36 minutes, significantly alleviating difficulties in falling asleep [2] - Continuous use of Manlejing® leads to improvements in both nighttime sleep and daytime behavior, helping to reduce issues such as hyperactivity, irritability, and inappropriate language [2] Group 2 - The International Pediatric Sleep Association (IPSA) and the American Academy of Neurology (AAN) recommend that children use pharmaceutical-grade melatonin, reinforcing the credibility of Manlejing® [2] - JD Health plans to leverage its robust pharmaceutical health service ecosystem to collaborate with Dain Pharmaceutical and other renowned companies to introduce cutting-edge therapeutic drugs, aiming to provide comprehensive digital health management solutions for affected children [2]

Core Viewpoint - The launch of Manlejing® Melatonin Granules by Dain Pharmaceutical in collaboration with Alibaba Health addresses sleep difficulties in children aged 6 to 15 with neurodevelopmental disorders, marking a significant outcome of their strategic partnership established in October 2023 [1][7]. Group 1: Product Launch and Market Need - Sleep disorders are common and challenging comorbidities in children with neurodevelopmental disorders, particularly in those with Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) [5]. - Long-term sleep difficulties severely impact children's growth, behavior, and emotional well-being, creating significant challenges for families [5]. - There is a limited availability of safe and effective medications specifically approved for this demographic in China, highlighting a critical clinical need [5]. Group 2: Clinical Data and Safety - Clinical data indicates that the use of Manlejing® can significantly shorten sleep onset latency and improve abnormal behaviors such as irritability and hyperactivity over long-term use [6]. - A six-month follow-up showed no serious adverse reactions, dependency, or withdrawal risks, making it suitable for long-term use in children [6]. Group 3: Strategic Collaboration and Future Plans - Dain Pharmaceutical aims to focus on the development and introduction of pediatric medications and health products, emphasizing a tailored approach to children's medications [6]. - Alibaba Health's role as a strategic partner is to connect with a vast potential user base and provide professional pharmaceutical services, ensuring safe medication use through authoritative content and strict prescription processes [6]. - The collaboration is part of Alibaba Health's strategy to deepen its engagement in vertical health management for specific populations, aiming to provide comprehensive solutions for pharmaceutical companies [7].